Teva FDA approval of Tamoxifen Citrate tablets
The US Food and Drug Administration has approved the company's ANDAs for Tamoxifen Citrate Tablets USP, 10 milligrams and 20 milligrams. Shipments will begin immediately.
Tamoxifen Citrate Tablets are the AB-rated generic equivalent of AstraZeneca's Nolvadex Tablets, an anti-estrogen drug for the treatment of breast cancer. Annual Tamoxifen sales in the USA are more than $500 million.
Teva Pharmaceutical Industries, headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Close to 90 percent of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. — (menareport.com)
© 2003 Mena Report (www.menareport.com)